AR032957A1 - Metodos para identificar compuestos para regular la masa o funcion muscular utilizando receptores del factor liberador de corticotropina - Google Patents
Metodos para identificar compuestos para regular la masa o funcion muscular utilizando receptores del factor liberador de corticotropinaInfo
- Publication number
- AR032957A1 AR032957A1 ARP020100806A ARP020100806A AR032957A1 AR 032957 A1 AR032957 A1 AR 032957A1 AR P020100806 A ARP020100806 A AR P020100806A AR P020100806 A ARP020100806 A AR P020100806A AR 032957 A1 AR032957 A1 AR 032957A1
- Authority
- AR
- Argentina
- Prior art keywords
- crf2r
- candidate compounds
- increase
- function
- muscle mass
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
Abstract
Un método para identificar compuestos candidatos para regular la masa o funcion muscular esquelética, que comprende: a) contactar un compuesto de prueba con un CRF2R, b) determinar si el compuesto de prueba se fija al CRF2R; y c) identificar aquellos compuestos candidatos para regular la masa o funcion muscular esquelética. Un método para identificar compuestos terapéuticos candidatos de un grupo de uno o más compuestos candidatos que se ha determinado previamente que se fijan a o activan el CRF2R. Un método para identificar compuestos candidatos que prolongan o aumentan la activacion inducida por agonista de un CRF2R o una vía de transduccion de senal de CRF2R. Un método para identificar compuestos candidatos para aumentar la expresion de CRF2R o CRF. Un método para aumentar la masa o funcion muscular esquelética en un sujeto en que el aumento es deseable. Un método para tratar la atrofia muscular esquelética en un sujeto que requiere de tal tratamiento. Un anticuerpo purificado específico para un CRF2R en donde el anticuerpo es un anticuerpo quimérico o humano. Una composicion farmacéutica que comprende a) una cantidad segura y eficaz de un agonista de CRF2R y b) un portador farmacéuticamente aceptable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/799,978 US6670140B2 (en) | 2001-03-06 | 2001-03-06 | Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR032957A1 true AR032957A1 (es) | 2003-12-03 |
Family
ID=25177205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020100806A AR032957A1 (es) | 2001-03-06 | 2002-03-06 | Metodos para identificar compuestos para regular la masa o funcion muscular utilizando receptores del factor liberador de corticotropina |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US6670140B2 (es) |
| EP (1) | EP1379873B1 (es) |
| JP (2) | JP4331942B2 (es) |
| KR (2) | KR100596991B1 (es) |
| CN (1) | CN100520408C (es) |
| AR (1) | AR032957A1 (es) |
| AT (1) | ATE429242T1 (es) |
| AU (1) | AU2002303121B2 (es) |
| BR (1) | BR0207881A (es) |
| CA (1) | CA2439170C (es) |
| CZ (1) | CZ20032395A3 (es) |
| DE (1) | DE60232063D1 (es) |
| ES (1) | ES2325485T3 (es) |
| HU (1) | HUP0402173A2 (es) |
| IL (1) | IL157330A0 (es) |
| MA (1) | MA26990A1 (es) |
| MX (1) | MXPA03008114A (es) |
| MY (1) | MY134755A (es) |
| NO (1) | NO20033936L (es) |
| NZ (1) | NZ527124A (es) |
| PE (1) | PE20020993A1 (es) |
| PL (1) | PL367187A1 (es) |
| RU (1) | RU2260805C2 (es) |
| SA (1) | SA02230159B1 (es) |
| SK (1) | SK12132003A3 (es) |
| TW (1) | TWI227780B (es) |
| WO (1) | WO2002069908A2 (es) |
| ZA (1) | ZA200305642B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2418144C (en) * | 2000-08-04 | 2013-06-18 | Research Development Foundation | Urocortin proteins and uses thereof |
| US20040049009A1 (en) * | 2000-09-22 | 2004-03-11 | Klaus Eckart | Methods for improving the antagonistic/agonistic properties of peptidic antagonists/agonists of the corticotropin-releasing factor receptor (crfr) |
| US6670140B2 (en) * | 2001-03-06 | 2003-12-30 | The Procter & Gamble Company | Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors |
| US6936585B2 (en) * | 2002-01-16 | 2005-08-30 | The Procter & Gamble Company | Corticotropin releasing factor 2 receptor agonists |
| WO2007090087A2 (en) * | 2006-01-27 | 2007-08-09 | Research Development Foundation | Use of corticotropin releasing factor receptor-2 inhibitors for treating insulin-related diseases |
| EP2114437A2 (en) * | 2006-10-16 | 2009-11-11 | ConjuChem Biotechnologies Inc. | Modified corticotropin releasing factor peptides and uses thereof |
| GB0624282D0 (en) * | 2006-12-05 | 2007-01-10 | Cavalla David | Treatment of cachexia |
| AU2008255927B2 (en) * | 2007-05-23 | 2012-12-13 | Nippon Chemiphar Co., Ltd. | G-protein-conjugated receptor having altered ligand affinity, and use thereof |
| US8334101B2 (en) * | 2008-09-26 | 2012-12-18 | University Of Massachusetts | Intracellular DNA receptor |
| CA3185480A1 (en) * | 2010-12-23 | 2012-06-28 | Amazentis Sa | Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders |
| RS56796B1 (sr) * | 2011-11-14 | 2018-04-30 | Regeneron Pharma | Kompozicije i postupci za uvećanje mišićne mase i jačine mišića specifičnim antagonizovanjem gdf8 i/ili aktivina a |
| RU2517259C1 (ru) * | 2013-03-06 | 2014-05-27 | Федеральное государственное бюджетное учреждение науки Государственный научный центр Российской Федерации - Институт медико-биологических проблем Российской академии наук (ГНЦ РФ-ИМБП РАН) | Способ профилактики и снижения деструкции белков скелетных мышц при их атрофии, вызванной гипокинезией и/или гравитационной разгрузкой |
| JP2015071549A (ja) * | 2013-10-02 | 2015-04-16 | 株式会社ファンケル | アトロジン−１抑制剤 |
| RU2568903C2 (ru) * | 2014-04-07 | 2015-11-20 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Алтайский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ оценки анаболического действия лекарственных препаратов |
| MA49661A (fr) | 2015-04-15 | 2020-06-03 | Regeneron Pharma | Méthode pour augmenter la résistance et la fonctionnalité avec des inhibiteurs de gdf-8 |
| WO2018075973A2 (en) * | 2016-10-20 | 2018-04-26 | Cortene Inc. | Methods of treating diseases resulting from a maladapted stress response |
| CN111787981A (zh) | 2018-03-01 | 2020-10-16 | 瑞泽恩制药公司 | 改变身体组成的方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4415558A (en) * | 1981-06-08 | 1983-11-15 | The Salk Institute For Biological Studies | CRF And analogs |
| US4533654A (en) * | 1982-09-29 | 1985-08-06 | The Salk Institute For Biological Studies | Urotensin peptides |
| US4489163A (en) * | 1983-04-14 | 1984-12-18 | The Salk Institute For Biological Studies | rCRF and analogs |
| US4594329A (en) * | 1984-05-14 | 1986-06-10 | The Salk Institute For Biological Studies | CRF analogs |
| US4605642A (en) * | 1984-02-23 | 1986-08-12 | The Salk Institute For Biological Studies | CRF antagonists |
| US4801612A (en) * | 1986-07-03 | 1989-01-31 | Regents Of The University Of California | Method of inhibiting inflammatory response |
| DE3703340A1 (de) * | 1987-02-04 | 1988-08-18 | Dirck Dr Med Oppermann | Pharmazeutische zubereitung zur behandlung der herzinsuffizienz |
| US4908352A (en) * | 1987-09-28 | 1990-03-13 | The Salk Institute For Biological Studies | Urotensin peptides |
| US5109111A (en) * | 1988-09-23 | 1992-04-28 | The Salk Institute For Biological Studies | CRF antagonists |
| US5278146A (en) * | 1988-09-30 | 1994-01-11 | The Salk Institute For Biological Studies | CRF analogs |
| CA1340964C (en) * | 1988-09-30 | 2000-04-18 | Jean E. F. Rivier | Crf analogs |
| US5235036A (en) | 1991-05-31 | 1993-08-10 | The Salk Institute For Biological Studies | Crf analogs |
| US5493006A (en) * | 1993-06-16 | 1996-02-20 | The Salk Institute For Biological Studies | Cyclic CRF analogs |
| US5728545A (en) * | 1993-06-18 | 1998-03-17 | The Salk Institute Of Biological Studies | Cloning and recombinant production of CRF receptor (S) |
| US6495343B1 (en) * | 1993-06-18 | 2002-12-17 | The Salk Institute For Biological Studies | Cloning and recombinant production of CRF receptor(s) |
| EP0860501A3 (en) | 1994-06-14 | 1999-05-19 | Neurocrine Biosciences, Inc. | Corticotropin-releasing factor2 receptors |
| ATE171212T1 (de) * | 1994-06-14 | 1998-10-15 | Neurocrine Biosciences Inc | Corticotropin freisetzende rezeptoren des faktor 2 |
| US5786203A (en) * | 1994-06-14 | 1998-07-28 | Neurocrine Biosciences, Inc. | Isolated nucleic acid encoding corticotropin-releasing factor2 receptors |
| US5824771A (en) | 1994-12-12 | 1998-10-20 | The Salk Institute For Biological Studies | Cyclic CRF agonists |
| US5663292A (en) | 1994-12-12 | 1997-09-02 | The Salk Institute For Biological Studies | Cyclic CRF analogs |
| US5660824A (en) | 1995-05-24 | 1997-08-26 | Grabstein; Kenneth H. | Muscle trophic factor |
| CA2223792A1 (en) | 1995-06-13 | 1997-01-03 | The Salk Institute For Biological Studies | Urocortin peptides |
| US5869450A (en) | 1996-03-06 | 1999-02-09 | The Regents Of The University Of California | Anti-inflammatory compositions and method with corticotropin-releasing factor analogs |
| US5888811A (en) * | 1996-05-23 | 1999-03-30 | Dupont Pharmaceuticals Company | Corticotropin-releasing hormone receptor |
| CA2338561A1 (en) * | 1998-07-24 | 2000-02-03 | Joachim Spiess | Antagonists specific for the corticotropin-releasing factor receptor type 2 (crfr2) |
| CA2418144C (en) * | 2000-08-04 | 2013-06-18 | Research Development Foundation | Urocortin proteins and uses thereof |
| US6670140B2 (en) * | 2001-03-06 | 2003-12-30 | The Procter & Gamble Company | Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors |
-
2001
- 2001-03-06 US US09/799,978 patent/US6670140B2/en not_active Expired - Lifetime
-
2002
- 2002-03-05 PE PE2002000176A patent/PE20020993A1/es not_active Application Discontinuation
- 2002-03-05 TW TW091104025A patent/TWI227780B/zh not_active IP Right Cessation
- 2002-03-06 MX MXPA03008114A patent/MXPA03008114A/es active IP Right Grant
- 2002-03-06 NZ NZ527124A patent/NZ527124A/en unknown
- 2002-03-06 MY MYPI20020802A patent/MY134755A/en unknown
- 2002-03-06 BR BR0207881-3A patent/BR0207881A/pt not_active IP Right Cessation
- 2002-03-06 JP JP2002569086A patent/JP4331942B2/ja not_active Expired - Fee Related
- 2002-03-06 RU RU2003129500/15A patent/RU2260805C2/ru not_active IP Right Cessation
- 2002-03-06 SK SK1213-2003A patent/SK12132003A3/sk unknown
- 2002-03-06 AT AT02731122T patent/ATE429242T1/de not_active IP Right Cessation
- 2002-03-06 HU HU0402173A patent/HUP0402173A2/hu unknown
- 2002-03-06 CN CNB028059271A patent/CN100520408C/zh not_active Expired - Fee Related
- 2002-03-06 KR KR1020037011659A patent/KR100596991B1/ko not_active IP Right Cessation
- 2002-03-06 CA CA2439170A patent/CA2439170C/en not_active Expired - Fee Related
- 2002-03-06 ES ES02731122T patent/ES2325485T3/es not_active Expired - Lifetime
- 2002-03-06 DE DE60232063T patent/DE60232063D1/de not_active Expired - Lifetime
- 2002-03-06 AU AU2002303121A patent/AU2002303121B2/en not_active Ceased
- 2002-03-06 IL IL15733002A patent/IL157330A0/xx unknown
- 2002-03-06 CZ CZ20032395A patent/CZ20032395A3/cs unknown
- 2002-03-06 AR ARP020100806A patent/AR032957A1/es not_active Application Discontinuation
- 2002-03-06 EP EP02731122A patent/EP1379873B1/en not_active Expired - Lifetime
- 2002-03-06 PL PL02367187A patent/PL367187A1/xx not_active Application Discontinuation
- 2002-03-06 WO PCT/US2002/007476 patent/WO2002069908A2/en active IP Right Grant
- 2002-03-06 KR KR1020067005678A patent/KR100598441B1/ko not_active IP Right Cessation
- 2002-06-19 SA SA02230159A patent/SA02230159B1/ar unknown
-
2003
- 2003-07-22 ZA ZA200305642A patent/ZA200305642B/en unknown
- 2003-08-07 MA MA27267A patent/MA26990A1/fr unknown
- 2003-08-27 US US10/649,852 patent/US7063954B2/en not_active Expired - Lifetime
- 2003-09-05 NO NO20033936A patent/NO20033936L/no not_active Application Discontinuation
-
2006
- 2006-04-26 US US11/412,025 patent/US7572768B2/en not_active Expired - Fee Related
-
2008
- 2008-09-01 JP JP2008224143A patent/JP2009029816A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR032957A1 (es) | Metodos para identificar compuestos para regular la masa o funcion muscular utilizando receptores del factor liberador de corticotropina | |
| EP1007556A4 (en) | TROPONIN SUB-UNITS AND FRAGMENTS FOR USE AS INHIBITORS OF ANGIOGENESIS | |
| AP0202539A0 (en) | Inhibitors of interleukin -1B converting enzyme | |
| BR0312785A (pt) | Tratamento de desordens relacionadas a tnf(alfa) | |
| RS20050298A (en) | Human anti-ifn-gama neutralizing antibodies as selective ifn -gama pathway inhibitors | |
| MY129189A (en) | Prostaglandin agonists and their use to treat bone disorders | |
| NO20042964L (no) | Spiroazasykliske forbindelser som monoaminreseptormodulatorer | |
| DK0800519T3 (da) | Steroidreceptormodulatorforbindelser og fremgangsmåder | |
| WO2004052348A3 (en) | Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds | |
| MX9704640A (es) | Compuesto moduladores de los receptores de los esteroides y metodos para su preparacion. | |
| MX9202943A (es) | Compuestos triciclo, proceso para prepararlos y composicion farmaceutica que los contiene. | |
| NO982062L (no) | Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav | |
| NO982774L (no) | Inhibitorer for Interleukin-1<beta>-konverterende enzym | |
| EP1855719A4 (en) | NEUTRALIZING MONOCLONAL ANTIBODIES TO CORONAVIRES IN CONNECTION WITH HEAVY ACUTE RESPIRATORY SYNDROME | |
| CL2003001814A1 (es) | Compuestos derivados de 1,3,8-triazaespiro[4,5]decan-4-ona jidroxialquil sustituidos, moduladores del receptor orl-1; compuestos intermediarios; composicion farmaceutica que contiene dichos compuestos; procedimiento de preparacion de la composicion f | |
| DK1461318T3 (da) | Tetrahydroquinolinanaloge som muscariniske agonister | |
| TNSN05158A1 (fr) | Association destinee au traitement de l'adhd | |
| DE69738613D1 (de) | Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten | |
| AP9801269A0 (en) | Prostaglandin agonists. | |
| GB9924957D0 (en) | Novel treatment | |
| BR0209920A (pt) | Composto ou sal farmaceuticamente aceitável do mesmo, métodos de tratar ansiedade, depressão ou estresse e sìndrome do intestino irritável ou doença de crohn, de detectar receptores de crf1 em uma primeira amostra biológica, de demonstrar a presença ou ausência de receptores de crf1 em uma amostra biológica e de inibir a ligação de crf a um receptor de crf1, composição farmacêutica, e, embalagem | |
| DE69836678D1 (de) | Chinolin- und chinazolinderivate als antagonisten des corticotropin freisetzenden faktors (crf) | |
| AR038143A1 (es) | Agonistas del receptor 2 del factor liberador de la corticotropina | |
| AU3422800A (en) | Use of 5-ht3 receptor antagonists | |
| EA200100930A1 (ru) | Способ лечения хозл |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |